In patients with heart failure, the gender difference was driven by higher 1-year CUPs of both SGLT2-inhibitors and GLP1 analogues, whereas the gender difference in PAD patients was mainly driven by the use of GLP-1 analogues (Additional file 2: Fig. S2b, c). This evidence concerns the gene SLC5A2 and heart failure.